In AD, for example, these multimodal strategies have already begun to reshape diagnostic pathways and patient follow-up, with the recent introduction of ultrasensitive blood tests aiming at measuring levels of amyloid β peptides, tau, glial fibrillar acidic protein (GFAP), and neurofilament light (NfL) protein 2 [109]. This evidence concerns the gene MAPT and Alzheimer disease.